<SEC-DOCUMENT>0001043961-19-000010.txt : 20190620
<SEC-HEADER>0001043961-19-000010.hdr.sgml : 20190620
<ACCEPTANCE-DATETIME>20190620170311
ACCESSION NUMBER:		0001043961-19-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190620
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190620
DATE AS OF CHANGE:		20190620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		19909126

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prpo-20190620x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.2.1.13-->
<!--Created on: 6/20/2019 5:01:22 PM-->
<html>
	<head>
		<title>
			PRPO-8K - Regulation FD Disclosure - June 19 Letter to Shareholders
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<div><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNITED STATES</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">WASHINGTON, D. C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">FORM 8-K </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">CURRENT REPORT<br />PURSUANT TO SECTION 13 OR 15(d) OF THE<br />SECURITIES EXCHANGE ACT OF 1934 </font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Date of report (Date of earliest event reported): June 17, 2019</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">PRECIPIO, INC.<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">(Exact Name of Registrant as Specified in Its Charter)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:128.60pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.20pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:158.40pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:128.60pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Delaware<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">(State of Incorporation)</font></p>
				</td>
				<td valign="top" style="width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.20pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:10pt;">001-36439<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">(Commission File Number)</font></p>
				</td>
				<td valign="top" style="width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:158.40pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:10pt;">91-1789357<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">(I.R.S. Employer Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">4 Science Park, New Haven, CT 06511</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">(Address of principal executive offices) (Zip Code)</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> (203) 787-7888</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">(Registrant's telephone number, including area code)</font>
		</p>
		<a name="page_de1292_1_2"></a><div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 5pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Not Applicable<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">(Former name, former address and former fiscal year, if changed since last report date)</font>
		</p>
		<div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:560.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ticker symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Common Stock, $0.01 par value per share</font></p>
				</td>
				<td valign="bottom" style="width:190.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">PRPO</font></p>
				</td>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">The Nasdaq Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 23pt 0pt 0pt;line-height:111.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 23pt 6pt 0pt;line-height:111.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 0.35pt;line-height:10.35pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Emerging growth company </font><font style="display:inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 8pt 6pt 0.35pt;line-height:10.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="display:inline;">&#x2610;</font>
		</p>
		<div><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Item 7.01 <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Regulation FD Disclosure</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">On June 17, 2019, Precipio, Inc (the "Company") issued a letter to its shareholders. A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#x201C;filed&#x201D; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Item 9.01 Financial Statements and Exhibits</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(d) Exhibits</font>
		</p>
		<p style="margin:0pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">99.1 <a href="prpo-20190620ex9918b5dd4.htm"></font><font style="display:inline;font-family:Times New Roman,Times,serif;">Precipio Inc&#x2019;s letter to shareholders dated&nbsp;&nbsp;June 17, 2019</a></font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SIGNATURE </font>
		</p>
		<p style="margin:12pt 0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:46.00%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">PRECIPIO, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:46.00%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="width:39.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">s/ Ilan Danieli </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="top" style="width:39.44%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ilan Danieli</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="top" style="width:39.44%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>June 20, 2019 &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prpo-20190620ex9918b5dd4.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.2.1.13-->
<!--Created on: 6/20/2019 5:01:26 PM-->
<html>
	<head>
		<title>
			PRPO - 8K - 991 Press release Letter to Shareholders June 19 2019
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:center;font-family:Calibri;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"><img src="prpo20190620ex9918b5dd4001.jpg" style="width: 4.270833in; height: 0.8125in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:center;font-family:Calibri;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Precipio CEO Provides Update Letter To Shareholders</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">NEW HAVEN, CT, (June 17, 2019) &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Specialty diagnostics company</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;text-decoration:none;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;">Precipio, Inc.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;"> &nbsp;(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">NASDAQ: PRPO</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">), provides an update to its shareholders. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Dear Investors:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">We are all aware of the recent pricing pressure on Precipio&#x2019;s stock. To this end, we would like to provide an update of both our business activities and to reiterate investor communication practices. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">Business Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">First, we would like to address the business activities surrounding our new products, IV-Cell and HemeScreen. Both products address critical, costly and lengthy diagnostic pathology challenges for cancer testing on a world-wide basis. Simply put, these products solve major clinical, operational, and cost issues that have existed for decades. Both IV-Cell and Hemescreen are proprietary to Precipio and have patents pending. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As the products we make are critical to diagnosing cancer, incorporating them into a manufacturing process or into the customer&#x2019;s laboratory work flow is a careful and precise process that requires in depth testing and validation, in order to ensure that accurate results are reached &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;text-decoration:underline;">as it should be</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">. Introducing these products by large companies we are working with, always takes longer than we hope for; often times smaller companies like us use our own rapid process as a proxy, and subsequently we underestimated the length of time to complete formal independent third-party validation studies and customer in-house reviews. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">With regard to the IV-Cell progress (and other technologies) - &nbsp;as recently announced, we&#x2019;ve identified the manufacturer for IV-Cell. As some of you correctly pointed out, &#x201C;why would we need such a manufacturer if we didn&#x2019;t anticipate large contracts?&#x201D;. This is a correct assumption and we are working with several customers both domestically and internationally to trial, validate and bring on board the media. As mentioned above, This is not a simple process, but once concluded we will be sure to inform the market. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">These validation studies are projected to be complete by late Q3, and (assuming successful validation), be converted into orders and subsequent revenues. While the delay is extremely disappointing, we can report that all outside testing results received so far have successfully replicated our internal data. &nbsp;As we progress and continue to achieve material milestones, we will issue additional investor communications. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Bottom line - Nothing has changed: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">These products work and deliver value </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Customers can benefit significantly from clinical, operational and cost benefits</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">We are engaged with major players at the highest level</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;vertical-align:baseline;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">We strongly believe this will convert into substantial revenue for the company</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">No Equity Raise</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Second, we would like to reiterate our prior announcements, that there are no plans to execute an equity raise. &nbsp;The company&#x2019;s cash reserves, combined with the September 2018 equity line are projected to provide sufficient operating runway to grow our pathology business, complete external product validation studies and successfully market IV-Cell and HemeScreen to our targeted customers. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Our goal is to continue to make strides towards cash flow positive there the company no longer needs to rely on outside capital sources to fund its operations. We believe that with our new suite of products such as IV-Cell and Hemscreen, generating good revenue and gross margin, this is achievable and within sight. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">News release policy</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;text-decoration:underline;">:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">The company has always attempted to provide feedback, information and transparency to all our shareholders. When we have material news, we are eager to share; we have never &#x201C;held back&#x201D; any news, have no reason to and do not intend to do so. Day-to-day we focus on building our business and expanding our technology. We believe we have the right business model, eliminating misdiagnosis of cancer through expertise and technologies we&#x2019;ve developed. Our mission is to create long-term value. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">In the past and most recently, we know we are under assault by the shorting interests. We stand firm in knowing that the best way to solve this issue is to create value through operating a growing and profitable business. Like you, we are pained by the abusive nature of shorting in the market. Unfortunately, the only tool we have at our disposal is continued results. While we know many of you would love to see news every day, we strongly believe that news must be meaningful and material in order for it to be impactful. We want to avoid the &#x201C;cry wolf&#x201D; situation. &nbsp;We are determined to reach the point where the market recognizes our value and responds accordingly and we are certain that this will be reflected in the share price. That day will come; you have mine and my team&#x2019;s commitment to that. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">To the investors who have been with us, creating value will not happen overnight; and it will not happen in a straight line &#x2013; there will be ups &amp; down, as is common for a micro-cap healthcare company. Many of you seem to think that the company has news and is &#x201C;holding back&#x201D;; or that the company is purposely delaying either the achievement, or announcement of results. This could not be further from reality. When we have material news regarding the business we share it.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As indicated in our recent metrics release, we are well poised for continued growth with regard to the pathology services growth. We will be tracking &amp; reporting these metrics quarterly, to continue to provide transparency to our shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">Going forward</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">: &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As mentioned above, we will continue to share pertinent information as quickly as I can. &nbsp;As always, we welcome you emails to our </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;">investors@precipiodx.com</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;"> email. Rest assured, we read each one. Like you, we are all shareholders, and my team and I have invested the past 8 years of our lives to build this important company. &nbsp;Whenever allowed by SEC regulations I personally purchase Precipio stock.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">In summary, we believe we are in a position to create long term value for our shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Thank you for your ongoing support.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As always at your service,</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Ilan Danieli</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">CEO, Precipio</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">About Precipio</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard&#x2019;s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;text-decoration:none;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">www.precipiodx.com</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Certain statements in this press release constitute &#x201C;forward-looking statements,&#x201D; within the meaning of federal securities laws, including statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and prospects and other statements containing the words &#x201C;anticipate,&#x201D; &#x201C;intend,&#x201D; &#x201C;may,&#x201D; &#x201C;plan,&#x201D; &#x201C;predict,&#x201D; &#x201C;will,&#x201D; &#x201C;would,&#x201D; &#x201C;could,&#x201D; &#x201C;should,&#x201D; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company&#x2019;s definitive proxy statement filed on April 19, 2019 , the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and on the Annual Report on Form 10-K for the year ended December 31, 2018 as well as the Company&#x2019;s prior filings and from time to time in the Company&#x2019;s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Inquiries:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;text-decoration:underline;">investors</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;">@precipiodx.com</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;background-color: #FFFFFF;">+1-203-787-7888</font>
		</p>
		<p style="margin:0pt 0pt 8pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;color:#222222;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<a name="_gjdgxs"></a><a name="_30j0zll"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>prpo20190620ex9918b5dd4001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 prpo20190620ex9918b5dd4001.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K C,# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_[_  _PH_X7?9_] 6?_ +_#_"O1?^$>T7_H#Z?_ . R?X4?\(]HO_0'T_\
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M&HI_'WQ,EUR>,BQM'$H!Z +_ *M/KD9/T-1Z[XCUCXE:NFBZ+"\6GJV2&XR
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
